$0.26
+0.03 (+11.12%)
Open$0.23
Previous Close$0.23
Day High$0.26
Day Low$0.22
52W High$10.49
52W Low$6.08
Volume—
Avg Volume620.2K
Market Cap46.36M
P/E Ratio46.40
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,428.7% upside
Current
$0.26
$0.26
Target
$11.77
$11.77
$8.46
$11.77 avg
$14.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.79M | 31.57M | 32.41M |
| Net Income | 827.5K | 932.2K | 975.1K |
| Profit Margin | 2.3% | 3.0% | 3.0% |
| EBITDA | 1.82M | 1.58M | 1.77M |
| Free Cash Flow | 629.7K | 483.5K | 562.4K |
| Rev Growth | +6.8% | +6.0% | -3.2% |
| Debt/Equity | 0.61 | 0.73 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |